EyePoint Pharmaceuticals
Presencia
EyePoint Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización EYPT (US).
Ejecutivos
Ver el organigrama con sus 20 ejecutivos principales
Biografías más buscadas en EyePoint Pharmaceuticals
- Jay Duker, President and Chief Executive Officer
- Wendy DiCicco, Director
- Nancy Lurker, Executive Vice Chairman of the Board
Recientes movimientos de ejecutivos en EyePoint Pharmaceuticals
- Ramiro Ribeiro, se ha incorporado a la empresa como Chief Medical Officer (noticia publicada el 5 de marzo de 2024).
- Dario Paggiarino, Senior Vice President & Chief Medical Officer, ha dejado la empresa (noticia publicada el 5 de marzo de 2024).
- Stuart Duty, se ha incorporado a la empresa como Director (noticia publicada el 17 de octubre de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en EyePoint Pharmaceuticals.
Equipos médicos
EyePoint Pharmaceuticals tiene 978 competidores entre los que se incluyen Philips (Países Bajos), Medtronic (Irlanda) y Thermo Fisher Scientific (Estados Unidos).
Popular M&A news in Equipos médicos
- Medigus cambiará su nombre a Xylo Technologies el Apr 12, 2024. (publicado el 12 de abril de 2024).
- Johnson & Johnson has announced the acquisition of Shockwave Medical (publicado el 6 de abril de 2024).
- Carlsmed acaba de anunciar una recaudación de fondos de 52 millones de dólares. (publicado el 22 de marzo de 2024).
Otros contactos sugeridos en el sector Equipos médicos
Noticias
Últimos comunicados de prensa de EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- Up and down the ladder: The latest comings and goings
- EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals appoints Ramiro Ribeiro as chief medical officer (NASDAQ:EYPT)
- Buy Rating Affirmed for EyePoint Pharmaceuticals Amid Strategic Leadership Changes and Promising Pipeline Outlook
- EyePoint Pharmaceuticals Welcomes New CMO Dr. Ramiro Ribeiro, Eyes Phase 3 Trials
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 | EyePoint Pharmaceuticals
- View more press releases Close
Redes sociales sobre EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- EyePoint Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Jay Duker 
Llame a EyePoint Pharmaceuticals al +1 617...
